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1. Introduction 
Nanoparticulate drug delivery systems (DDS) have attracted a lot of attention because of 
their size-dependent properties. Among the array of nanoparticles being currently 
investigated by pharmaceutical scientists, lipid nanoparticles have taken the lead because of 
obvious advantages of higher degree of biocompatibility and versatility. These systems are 
commercially viable to formulate pharmaceuticals for topical, oral, pulmonary or parenteral 
delivery. Lipid nano formulations can be tailored to meet a wide range of product 
requirements dictated by disease condition, route of administration and considerations of 
cost, product stability, toxicity and efficacy. The proven safety and efficacy of lipid-based 
carriers make them attractive candidates for the formulation of pharmaceuticals, as well as 
vaccines, diagnostics and nutraceuticals [1]. 
The most frequent role of lipid-based formulations has traditionally been to improve the 
solubility of sparingly water soluble drugs especially Biopharmaceutics Classification 
System (BCS) Classes II & IV drugs.  However, the spectrum of applications for lipid-based 
formulations has widened as the nature and type of active drugs under investigation vary. 
Lipid-based formulations may also protect active compounds from biological degradation 
or transformation, that in turn can lead to an enhancement of drug potency. In addition, 
lipid-based particulate DDS have been shown to reduce the toxicity of various drugs by 
changing the biodistribution of the drug away from sensitive organs. This reduction in 
toxicity may allow for more drug to be administered and forms the basis for the current 
success of several marketed lipid-based formulations of amphotericin B (Ambisome®, 
Abelcet®) and doxorubicin (Doxil®, Myocet®) [1]. 
Rapid advances in the ability to produce nanoparticles of uniform size, shape, and 
composition have started a revolution in science. The development of lipid-based drug carriers 
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has attracted increased attention over the last decade. Lipid nanoparticles (e.g. solid lipid 
nanoparticles, SLNs) are at the forefront of the rapidly developing field of nanotechnology 
with several potential applications in drug delivery, clinical medicine and research, as well as 
in other varied sciences. Due to their size-dependent properties, lipid nanoparticles offer the 
possibility to develop new therapeutics that could be used for secondary and tertiary level of 
drug targeting. Hence, lipid nanoparticles hold great promise for reaching the goal of 
controlled and site specific drug delivery and has attracted wide attention of researchers. 
At the turn of the millennium, modifications of SLN, nanostructured lipid carriers (NLC) 
and lipid drug conjugate (LDC)-nanoparticles were introduced [2, 3] in addition to liquid 
crystal DDS. These carrier systems overcome observed limitations of conventional SLN and 
more fluid lipid DDS. Compared to liposomes and emulsions, solid particles possess some 
advantages, e.g. protection of incorporated active compounds against chemical degradation 
and more flexibility in modulating the release of the compound. This paper focuses on the 
different lipid based nano systems, their structure and associated features, stability, 
production methods, drug incorporation and other issues related to their formulation and use 
in drug delivery. The following advantages among others, could be ascribed to lipid based 
nanocarriers: 
• ability to control and target drug release. 
• ability to improve stability of pharmaceuticals. 
• ability to encapsulate high drug content (compared to other carrier systems e.g. 
polymeric nanoparticles). 
• the feasibility of carrying both lipophilic and hydrophilic drugs. 
• most of the lipids used are biodegradable, and as such they have excellent 
biocompatibility, are non-toxic, non-allergenic and non-irritating. 
• they can be formulated by water-based technologies and thus can avoid organic 
solvents. 
• they are easy to scale-up and sterilize. 
• they are less expensive than polymeric/surfactant based carriers. 
• they are easy to validate. 
2. Drug delivery systems 
A drug delivery system is defined as a formulation or a device that enables the introduction 
of a therapeutic substance in the body and improves its efficacy and safety by controlling 
the rate, time, and place of release of drugs in the body. The process of drug delivery 
includes the administration of the therapeutic product, the release of the active ingredients 
by the product, and the subsequent transport of the active ingredients across the biological 
membranes to the site of action. DDS interface between the patient and the drug. It may be a 
formulation of the drug or a device used to deliver the drug [4]. 
3. Lipids 
The carboxylic acid group of a fatty acid molecule provides a convenient place for linking 
the fatty acid to an alcohol, via an ester linkage. If the fatty acid becomes attached to an 
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alcohol with a long carbon chain, the resultant substance is called a wax. When glycerol and 
a fatty acid molecule are combined, the fatty acid portion of the resultant compound is 
called an acyl group, and the glycerol portion is referred to as a glyceride. A triacylglyceride 
thus has three fatty acids attached to a single glycerol molecule. Sometimes, this name is 
shortened to triglyceride. Triglyceride substances are commonly referred to as fats or oils, 
depending on whether they are solid or liquid at room temperature [5]. A lipid is thus a 
fatty or waxy organic compound that is readily soluble in non-polar solvents (e.g. ether), but 
not in polar solvent (e.g. water). Examples of lipids are waxes, oils, sterols, cholesterol, fat-
soluble vitamins, monoglycerides, diglycerides, triglycerides (fats), and phospholipids. Fatty 
acids (including fats) are a subgroup of lipids, hence, it will be inaccurate to consider the 
terms synonymous.  
3.1. Classification of solid lipids for delivery of bioactives 
Lipids can be grouped into the following categories based upon their chemical composition. 
3.1.1. Homolipids 
Homolipids are esters of fatty acids with alcohols. They are lipids containing only carbon 
(C), hydrogen (H), and oxygen (O), and as such are referred to as simple lipids. The 
principal materials of interest for oral delivery vehicle are long chain and medium chain 
fatty acids linked to a glycerol molecule, known as triacylglycerols. The long-chain fatty 
acids ranging from C14 to C24 appear widely in common fat while the medium chain fatty 
acids ranging from C6 to C12 are typical components of coconut oil or palm kernel oil [6]. 
Examples of homolipids include: cerides (waxes e.g. beeswax, carnauba wax etc.), glycerides 
(e.g. fats and oils) and sterides (e.g. the esters of cholesterol with fatty acids). 
3.1.2. Heterolipids 
Heterolipids are lipids containing nitrogen (N) and phosphorus (P) atoms in addition to the 
usual C, H and O e.g. phospholipids, glycolipids and sulfolipids. They are also known as 
compound lipids. The emphasis here will be on the phospholipids only. Two main classes of 
phospholipids occur naturally in qualities sufficient for pharmaceutical applications. These 
are the phosphoglycerides and phosphosphingolipids. Some phosphosphingolipids such as 
ceramide are used mainly in topical dosage forms. Phospholipids can be obtained from all 
types of biomass because they are essential structural components in all kinds of membranes 
of living organisms [6].  
3.1.3. Complex lipids 
The more complex lipids occur closely linked with proteins in cell membranes and 
subcellular particles. More active tissues generally have a higher complex lipid content. 
They may also contain phospholipids. Complex lipids in this context include lipoproteins, 
chylomicrons, etc. Lipoproteins are spherical lipid-protein complexes that are responsible 
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for the transport of cholesterol and other lipids within the body. Structurally, lipoprotein 
consists of an apolar core composed of cholesterol esters or triacylglycerols, surrounded by 
monolayer of phospholipid in which cholesterol and one or more specific apoproteins are 
embedded e.g. chylomicrons and lipoproteins 
3.2. Lipid drug delivery systems 
Lipid-based DDS are an accepted, proven, commercially viable strategy to formulate 
pharmaceuticals for topical, oral, pulmonary or parenteral delivery. Lipid formulations can 
be tailored to meet a wide range of product requirements. One of the earliest lipid DDS- 
liposomes have been used to improve drug solubility. Currently, some companies have 
established manufacturing processes for the preparation of large scale batches of sparingly 
soluble compounds, often at drug concentrations several orders of magnitude higher than 
the nominal aqueous solubility because of the introduction of novel lipid-based DDS [1]. 
3.3. Lipid nanoparticulate drug delivery systems 
Lipid nanoparticles show interesting nanoscale properties necessary for therapeutic 
application. Lipid nanoparticles are attractive for medical purposes due to their important 
and unique features, such as their surface to mass ratio that is much larger than that of other 
colloidal particles and their ability to bind or adsorb and carry other compounds. Lipid nano 
formulations produce fine dispersions of poorly water soluble drugs and can reduce the 
inherent limitations of slow and incomplete dissolution of poorly water soluble drugs (e.g. 
BCS II & IV drugs), and facilitate formation of solubilised phases from which drug 
absorption occurs. In any vehicle mediated delivery system (whether the vehicle is an 
emulsion, liposome, noisome or other lipidic systems), the rate and mode of drug release 
from the system is important in relation to the movement of the delivery system in vivo. 
Lipid particulate DDS abound depending on their architecture and particle size. Due to the 
large number of administration routes available, these delivery systems perform differently 
depending on the formulation type and route of administration. Figure 1 shows some of the 
different lipid particulate DDS available. 
3.3.1. Solid lipid nanoparticles (SLN) 
SLN are particulates structurally related to polymeric nanoparticles. However, in contrast to 
polymeric systems, SLN can be composed of biocompatible lipids that are physiologically 
well tolerated when administered in vivo and may also be prepared without organic 
solvents. The lipid matrices can be composed of fats or waxes (homolipids) that provide 
protection to the incorporated bioactive from chemical and physical degradation, in 
addition to modification of drug release profile. Typical formulations utilize lipids such as 
paraffin wax or biodegradable glycerides (e.g. Compritol 888 ATO) as the structural base of 
the particle [7].  
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Figure 1. Lipid particulate drug delivery systems  
SLN were developed in the 1990s as an alternative carrier system to the existing traditional 
carriers, such as emulsions, liposomes and polymeric nanoparticles. SLN are prepared either 
with physiological lipids or lipids with generally regarded as safe (GRAS) status. Under 
optimized conditions they can incorporate lipophilic or hydrophilic drugs and seem to fulfil 
the requirements for an optimum particulate carrier system [8]. SLN have a potential wide 
application spectrum- parenteral administration and brain delivery, ocular delivery, rectal 
delivery, oral delivery, topical delivery and vaccine delivery systems etc., in addition to 
improved bioavailability, protection of sensitive drug molecules from the outer environment 
and even controlled release characteristics. Common disadvantages of SLN are particle 
growth, unpredictable gelation tendency, unexpected dynamics of polymorphic transitions 
and inherent low incorporation rate due to the crystalline structure of the solid lipid [9]. 
3.3.2. Nanostructured lipid carriers (NLC) 
NLC are colloidal carriers characterized by a solid lipid core consisting of a mixture of solid 
and liquid lipids, and having a mean particle size in the nanometer range. They consist of a 
lipid matrix with a special nanostructure [10]. This nanostructure improves drug loading 
and firmly retains the drug during storage. NLC system minimizes some problems 
associated with SLN such as low payload for some drugs; drug expulsion on storage and 
high water content of SLN dispersions. 
The conventional method for the production of NLC involves mixing of spatially very 
different lipid molecules, i.e. blending solid lipids with liquid lipids (oils). The resulting 
matrix of the lipid particles shows a melting point depression compared with the original 
solid lipid but the matrix is still solid at body temperature. Depending on the method of 
production and the composition of the lipid blend, different types of NLC are obtained. The 
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basic idea is that by giving the lipid matrix a certain nanostructure, the payload for active 
compounds is increased and expulsion of the compound during storage is avoided. Ability 
to trigger and even control drug release should be considered while mixing lipids to 
produce NLC. Newer methods of generating NLC are being developed. 
3.3.3. Lipid drug conjugates (LDC)-nanoparticles 
A major problem of SLN is the low capacity to load hydrophilic drugs due to partitioning 
effects during the production process. Only highly potent low dose hydrophilic drugs may 
be suitably incorporated in the solid lipid matrix [11]. In order to overcome this limitation, 
LDC nanoparticles with drug loading capacities of up to 33% were developed [8]. An 
insoluble drug-lipid conjugate bulk is first prepared either by salt formation (e.g. with a 
fatty acid) or by covalent linking (e.g. to ester or ethers). The obtained LDC is then processed 
with an aqueous surfactant solution to nanoparticle formulation by high pressure 
homogenization (HPH). Such nanoparticles may have potential application in brain 
targeting of hydrophilic drugs in serious protozoal infections [12].  
3.3.4. Liposomes 
Liposomes are closed vesicular structures formed by bilayers of hydrated phospholipids. 
The bilayers are separated from one another by aqueous domains and enclose an aqueous 
core. As a consequence of this alternating hydrophilic and hydrophobic structure, liposomes 
have the capacity to entrap compounds of different solubilities. Additionally, the basic 
liposome structure of hydrated phospholipid bilayers is amenable to extensive modification 
or 'tailoring' with respect to the physical and chemical composition of the vesicle. This 
versatility has resulted in extensive investigation into the use of liposomes for various 
applications such as in radiology, cosmetology and vaccinology. 
Liposomes used in drug delivery typically range from 25 nm to several micrometers and are 
usually dispersed in an aqueous medium. There are various nomenclatures for defining 
liposome subtypes based either on structural parameters or the method of vesicle 
preparation. These classification systems are not particularly rigid and a variation exists in 
use the of these terms, particularly with respect to size ranges. Liposomes are often 
distinguished according to their number of lamellae and size. Small unilamellar vesicles 
(SUV), large unilamellar vesicles and large multilamellar vesicles or multivesicular vesicles 
are differentiated. SUVs with low particle sizes in the nanometer range are of interest as 
liposomal nanocarriers for drug and antigen delivery [13, 14]. 
3.3.5. Transfersomes 
Transfersome technology was developed with the intention of providing a vehicle to allow 
delivery of bioactive molecules through the dermal barrier. Transfersomes are essentially 
ultra-deformable liposomes, composed of phospholipids and additional 'edge active' 
amphiphiles such as bile salts that enable extreme distortion of the vesicle shape. The vesicle 
 
Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development 113 
diameter is in the order of 100 nm when dispersed in buffer [15]. These flexible vesicles are 
thought to permeate intact through the intact dermis under the forces of the hydrostatic 
gradient that exists in the skin [16]. Drug or antigen may be incorporated into these vesicles 
in a manner similar to liposomes.  
3.3.6. Niosomes 
Niosomes are vesicles composed mainly of non-ionic bilayer forming surfactants [17]. They 
are structurally analogous to liposomes, but the synthetic surfactants used have advantages 
over phospholipids in that they are significantly less costly and have higher chemical 
stability than their naturally occurring phospholipid counterparts [18]. Niosomes are 
obtained on hydration of synthetic non-ionic surfactants, with or without incorporation of 
cholesterol or other lipids. Niosomes are similar to liposomes in functionality and also increase 
the bioavailability of the drug and reduce the clearance like liposomes. Niosomes can also be 
used for targeted drug delivery, similar to liposomes. As with liposomes, the properties of the 
niosomes depend both on the composition of the bilayer and the method of production. 
Antigen and small molecules have also been delivered using niosomes [19, 20].  
3.3.7. Liquid crystal drug delivery systems  
The spontaneous self assembly of some lipids to form liquid crystalline structures offers a 
potential new class of sustained release matrix. The nanostructured liquid crystalline 
materials are highly stable to dilution. This means that they can persist as a reservoir for 
slow drug release in excess fluids such as the gastrointestinal tract (GIT) or subcutaneous 
space, or be dispersed into nanoparticle form, while retaining the ‘parent' liquid crystalline 
structure. The rate of drug release is directly related to the nanostructure of the matrix. 
Lyotropic liquid crystal systems that commonly consist of amphiphilic molecules and 
solvents can be classified into lamellar (Lα), cubic, hexagonal mesophases, etc. In recent 
years, lyotropic liquid crystal systems have received considerable attention because of their 
excellent potential as drug delivery vehicles [21]. Among these systems, reversed cubic (QII) 
and hexagonal mesophases (HII) are the most important and have been extensively 
investigated for their ability to sustain the release of a wide range of bioactives from low 
molecular weight drugs to proteins, peptides and nucleic acids.  
3.3.8. Nanoemulsions  
Lipid-based formulations present a large range of optional delivery systems such as 
solutions, suspensions, self-emulsifying systems and nanoemulsions. Among these 
approaches, oral nanoemulsions offer a very good alternative because nanoemulsions can 
improve the bioavailability by increasing the solubility of hydrophobic drugs and are now 
widely used for the administration of BCS class II and class IV drugs. Oral nanoemulsions 
use safe edible materials (e.g., food-grade oils and GRAS-grade excipients) for formulation 
of the delivery system. Nanoemulsions possess outstanding ability to encapsulate active 
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compounds due to their small droplet size and high kinetic stability [22, 23]. Nanoemulsions 
have sizes below 1 µm and have been extensively investigated as novel lipid based DDS [22] 
together with microemulsions. 
3.4. Functional properties of lipids used in formulating lipid drug delivery 
systems 
3.4.1. Crystallinity and polymorphism of lipids 
Many pharmaceutical solids exist in different physical forms. It is well recognised that drug 
substances and excipients can be amorphous, crystalline or anhydrous, at various degrees of 
hydration or solvated with other entrapped solvent molecules, as well as varying in crystal 
hardness, shape and size. Amorphous solids consist of disordered arrangements of 
molecules and do not possess a distinguishable crystal lattice. In the crystalline state 
(polymorphs, solvates/hydrates, co-crystals), the constituent molecules are arranged into a 
fixed repeating array built of unit cells, which is known as lattice. Possession of adequate 
crystallinity is a prerequisite for a good lipid particulate DDS. 
Triglycerides, which are mainly used as lipid matrices crystallize in different polymorphic 
forms. The most important forms are the α and β forms. Since the formulation of lipid 
particulate DDS may involve melting at some point, recrystallization from the melt results 
in the metastable α-polymorph, which subsequently undergoes a polymorphic transition 
into the stable β-form via a metastable intermediate form (β') [24]. The β-polymorph 
especially consists of a highly ordered, rigid structure with low loading capacity for drugs. 
The formation of all these polymorphic forms has been proved amongst solid triglyceride 
nanoparticles [25].  
3.4.2. Melting characteristics of lipid matrices 
A pure triacylglycerol has a single melting point that occurs at a specific temperature. 
Nevertheless, certain lipids contain a wide variety of different triacylglycerols, with 
different melting points and as a result, they melt over a wide range of temperatures, 
producing a wide endothermic transition in differential scanning calorimeter. High purity 
lipids with sharp melting transitions exclude drugs on recrystallization. In addition to the 
solidity or melting point of each individual triglyceride, in drug delivery, we are interested 
and concerned with the combination of triglycerides throughout the fat mixture. This 
impacts the plasticity and the melting point range. In the development of lipid 
nanoparticles, lipids with melting points well above the body temperature are preferred. 
This will enable among others, sustained release of the encapsulated drug.  
3.5. Crystallinity and polymorphism vs drug loading capacity and drug release 
Crystallinity and polymorphism have a lot of influence on some properties of lipid matrices 
used in lipid DDS. Parameters like drug loading capacity and drug release depend highly 
on the crystallinity and the polymorphic form of the lipids. The crystalline order and density 
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increase from α to β forms and are highest for the β-forms of polymorphic lipids [24]. An 
increasing crystalline order has a great impact on the drug loading capacity, since an 
increase in order reduces the ability to incorporate different molecules including drugs [24]. 
Hence, the drug loading capacity of the poorly organized polymorphic forms is high [26]. 
However, this advantage goes along with the particles being in a metastable form which are 
able to transform into the stable β-polymorph upon storage. As a consequence of this 
transformation, often drug expulsion occurs. The increasing order of the matrix also reduces 
the diffusion rate of a drug molecule within the particle and hence reduces the rate of drug 
release.  
3.6. Strategies to improve drug loading in lipid particulate drug delivery systems 
The high crystallinity of SLN leads to a rather low drug loading capacity for many drugs, a 
problem still being addressed. However, for lipophilic drugs the incorporation into the 
particles is much easier and often results in rather high drug loading. In order to overcome 
the disadvantage of low loading capacity, many investigations have been done. Müller et al. 
[10] introduced NLC. In these formulations, lipids of highly ordered crystalline structure are 
combined with chemically different lipids of amorphous structure, giving rise to structured 
matrices that accommodate more drug.  
Friedrich et al [27] reported a different method to increase the drug payload by 
incorporating amphiphilic phospholipids into the lipid matrix. This resulted in a much 
higher solubility of the drug in the matrix, which was attributed to the formation of a 
solidified reverse micellar solution within the matrix. In this case, the nanoparticles were 
prepared by cold homogenization which may have prevented a redistribution of the lecithin 
to the surface of the particles or into the aqueous phase. Such a behaviour could be observed 
for a similar system after high pressure homogenization of the molten lipids [28]. 
Another mechanism of increasing the drug loading capacity of SLN has been recently 
developed [29-32]. In these works, the researchers used mixtures of solid lipids of natural 
origin possessing fatty acids of different chain lengths. In the analytical characterization of 
the lipid mixtures using differential scanning calorimetry (DSC), X-ray diffraction and 
isothermal microcalorimetery, it was observed that the mixtures were able to form matrices 
of imperfect structure composed of mixed crystals and mixtures of crystals, which enhanced 
drug incorporation compared with the single lipids. 
3.7. Ingredients used in the formulation of lipid based particulate drug delivery 
systems 
3.7.1. Emulsifiers 
Emulsifiers are essential to stabilize lipid nanoparticle dispersions and prevent particle 
agglomeration. The choice of the ideal surfactant for a particular lipid matrix is based on the 
surfactant properties such as charge, molecular weight, chemical structure, and respective 
hydrophile-lipophile balance (HLB). The HLB of an emulsifier is given by the balance 
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between the size and strength of the hydrophilic and the lipophilic groups. Table 1 shows 
some of the emulsifiers employed in the production of lipid nanoparticles. The choice of the 
emulsifiers depends on the route of administration of the formulation, for e.g. for 
parenteral formulations, there are limits of the emulsifiers to be used [33]. For topical and 
ocular route the issue of skin sensitization has to be considered, while for oral route, the 
emulsifier should not produce any physiological effect at the use concentration. 
Emulsifiers could be used in combination to produce synergistic effect and better stabilize 
the formulation [22]. 
 
Emulsifiers/coemulsifiers HLB References  
Lecithin 4-9 [9] 
Poloxamer 188 29 [34] 
Poloxamer 407 21.5 [35] 
Polysorbate 20 16.7 [36] 
Polysorbate 65 10.5 [7] 
Polysorbate 80 15 [9] 
Cremophor EL 12-14 [37] 
Solutol HS 15 15 [28] 
Table 1. Some emulsifiers used for the production of lipid nanoparticles 
3.7.2. Lipids 
The matrices for lipid nanoparticle preparation are natural, semi-synthetic or synthetic 
lipids which can be biodegradable, including triglyceride (tri-stearic acid, tri-palmitic acid, 
tri-lauric acid and long-chain fatty acid), steroid and waxes (e.g. beeswax, carnauba wax, 
etc) and phospholipids. They could be used singly or in combination. Lipids for the 
production of nanoparticles may be grouped into two: bilayer and non-bilayer lipids. 
3.7.3. Bilayer lipids used in drug delivery  
Some lipids are capable of adopting a certain orientation depending on the processing 
condition. Compounds that have approximately equal-sized heads and tails e.g. 
phospholipids (Figures 2 and 3) tend to form bilayers instead of micelles in aqueous system. 
In these structures, two monolayers of lipid molecules associate tail to tail, thus minimizing 
the contact of the hydrophobic portions with water and maximizing hydrophilic interactions 
[38] (Figure 3). The phospholipid molecules can move about in their half the bilayer, but 
there is a significant energy barrier preventing migration to the other side of the bilayer. 
Cholesterol can insert into the bilayer, and this helps to regulate the fluidity of the 
membrane. The self-assembled nature of lipid bilayers implies that they are normally in a 
tension-less state. 
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Figure 2. Structure of phospholipid (phosphatidylcholine) [Ref. 39].  
 
Figure 3. Interaction of phospholipid with water [38]. 
Phospholipids with certain head groups e.g. phosphatidylcholine (Figure 2) [39], can alter 
the surface chemistry of a lipid particle. The packing of phospholipid chains within the 
surface of the particle also affects its mechanical properties, including swelling, stretching, 
Tail 1 Head group 
Tail 2
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bending and deformability. Many of these properties have been taken advantage of in the 
design of novel lipid particulate DDS such as surface modification for improved drug 
loading capacity [31, 32, 40]. Deformability has been utilized in the development of ultra-
deformable liposomes termed transfersomal DDS (transfersomes). Cholesterol strengthens 
the bilayer but decrease its permeability. Bilayer lipids when present in lipid particulate 
DDS may define the boundaries of the particle and its environment (aqueous), and are often 
involved in many complex processes occurring at the interface.  
3.7.4. Non-bilayer lipids used in drug delivery 
In many biological systems, the major lipids are non-bilayer lipids, which in purified form 
cannot be arranged in a lamellar structure in the presence of aqueous systems. The 
structural and functional roles of these lipids in drug delivery are mainly in their utilization 
as matrix-forming lipids. They include such lipids as homolipids e.g. triglycerides and 
waxes. Their functional properties in lipid nanotechnology differs depending partly on their 
melting points, crystallinity and polymorphic characteristics. However, they may have 
absorption promoting properties especially for lipophilic drugs. Table 2 shows some of the 
non-bilayer lipids used in the formulation of lipid micro- and nanoparticles. 
 
Hard fats e.g.  Natural hard fats e.g. 
            
                 Stearic acid [Ref. 41] 
                 Palmitic acid [Ref. 42] 
                 Behenic acid [Ref. 43]
           Goat fat [Ref. 45] 
           Theobroma oil [Ref. 53] 
Triglycerides e.g. Waxes e.g.
         Trimyristin (Dynasan 114) [Ref. 44] 
         Tripalmitin (Dynasan 116) [Ref. 45] 
         Tristearin (Dynasan 118) [Ref. 44] 
         Trilaurin [Ref. 46]
           Beeswax [Ref. 9] 
           Cetyl palmitate [Ref. 47] 
           Carnauba wax [Ref. 89] 
Mono, di and triglycerides mixtures e.g.
                                   Witepsol bases [Ref. 48] 
                                   Glyceryl monostearate (Imwitor 900) [Ref. 49] 
                                   Glyceryl behenate (Compritol 888 ATO) [Ref. 50] 
                                   Glyceryl palmitostearate (Precirol ATO 5) [Ref. 51] 
                                   Softisan 142 and Softisan 154 [Refs. 52, 27] 
Table 2. Some non-bilayer lipids used in the formulation of lipid nanoparticles 
3.8. Characterization and selection of lipids for particulate drug delivery systems 
There is an increasing interest in lipid-based DDS due to factors such as better 
characterization of lipidic excipients and formulation versatility and the choice of different 
DDS. Apart from the fatty acid profile of previously undefined lipids, many different 
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analytical procedures are used to characterize lipids. These technologies provide different 
scales of analysis and may be used in combination to select the appropriate lipid matrix for 
use in formulation. DSC is the most widely used thermo-analytic technique for studying 
fats, oils and their mixtures. It gives information about the temperatures and energy 
associated with their fusion and crystallization, phase behaviour, polymorphic 
transformations, and data to estimate solid fat contents. DSC reports the destruction of 
structures in recordings obtained in a permanent out-of-equilibrium state. X-ray diffraction 
(small angle X-ray diffraction, SAXD and wide angle X-ray diffraction, WAXD) is also an 
essential tool for elucidating properties of fats and their mixtures. However, it complements 
DSC. XRD recordings provide both short and long spacings at a given temperature at which 
the sample is supposed to be in equilibrium. Since lipid systems are quite sensitive to their 
preparation history, only simultaneous recordings of SAXD, WAXD, and DSC circumvent 
the problem of reproducibility and guarantee identical conditions for all three 
measurements whatever may be the thermal treatment of the sample. Polarized light 
microscopy (PLM) is an analytical technique used in characterization of fats to observe the 
microstructures of the various polymorphic forms of fats. With a hot stage coupled, it is 
used to observe the microstructural changes in fats during melting, as the lipid passes from 
crystalline phase to isotropic phase, to visualize crystallization from isotropic melts and to 
visually detect undissolved drug crystals in the lipid matrix.  
Isothermal microcalorimetry (IMC) is a recent and an important tool in studying the time 
dependent crystallization of lipids and lipid matrices. It has been applied in both pure and 
mixed systems. Isothermal crystallization kinetics studies of mixtures of lipids using IMC 
also address the question of how the crystallinity of one component affects the 
crystallization behaviour of the other [29, 52, 53]. Atomic force microscopy (AFM) can 
provide invaluable information about the physicochemical characteristics of the carriers that 
play an important role in determining the performance of the DDS. A lot of this information 
cannot be obtained from other characterization techniques due to the unique ability of the 
atomic force microscope to probe nanometer scale features at the molecular level.  
3.9. Preparation of lipid nanoparticulate drug delivery systems 
There many methods for the preparation of lipid nanoparticulate DDS. The method used is 
dictated by the type of drug especially its solubility and stability, the lipid matrix, route of 
administration, etc. Liposomal preparation follows a different method as described by 
Mozafari [54]. In this section, emphasis was laid on the production of SLN, NLC and LDC-
nanoparticles, with methods that can also be applied to the formulation of liquid crystal 
DDS. 
3.9.1. High pressure homogenization 
High pressure homogenisation (HPH) is a suitable method for the preparation of SLN, NLC 
and LDC-nanoparticles and can be performed at elevated temperature (hot HPH technique) 
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or at and below room temperature (cold HPH technique) [11, 55]. The particle size is 
decreased by impact, shear, cavitation and turbulence. Briefly, for the hot HPH, the lipid 
and drug are melted (approximately 10 oC above the melting point of the lipid) and 
combined with an aqueous surfactant solution at the same temperature. A hot pre-emulsion 
is formed by homogenisation (e.g. using Ultra-Turrax). The hot pre-emulsion is then 
processed in a temperature-controlled high pressure homogenizer at 500 bar (or more) and 
predetermined number of cycles. The obtained nanoemulsion recrystallizes upon cooling 
down to room temperature forming SLN, NLC or LDC-nanoparticles. The cold HPH is a 
suitable technique for processing heat-labile drugs or hydrophilic drugs. Here, lipid and 
drug are melted together and then rapidly ground under liquid nitrogen forming solid lipid 
microparticles. A pre-suspension is formed by homogenisation of the particles in a cold 
surfactant solution. This pre-suspension is then further homogenised in a HPH at or below 
room temperature at predetermined homogenisation conditions to produce SLN, NLC or 
LDC-nanoparticles. The possibility of a significant increase in temperature during cold 
homogenisation should be borne in mind. Both HPH techniques are suitable for processing 
lipid concentrations of up to 40% and generally yield very narrow particle size distributions 
[56]. A schematic representation of HPH method of lipid particle preparation is shown in 
Figure 4. 
3.9.2. Production of SLN via microemulsions 
Gasco [57] developed and optimised a suitable method for the preparation of SLN via 
microemulsions. In a typical process, a warm microemulsion is prepared and thereafter, 
dispersed under stirring in excess cold water (typical ratio about 1:50) using a specially 
developed thermostated syringe. The excess water is removed either by ultra-filtration or by 
lyophilisation in order to increase the particle concentration. Experimental process parameters 
such as microemulsion composition, dispersing device, effect of temperature and 
lyophilisation on size and structure of the obtained SLN should be optimized. The removal of 
excess water from the prepared SLN dispersion is a difficult task with regard to the particle 
size. Also, high concentrations of surfactants and cosurfactants (e.g. butanol) are necessary for 
the formulation, but less desirable with respect to regulatory purposes and application. 
3.9.3. SLN prepared by solvent emulsification/evaporation 
For the production of nanoparticle dispersions by solvent emulsification/evaporation, the 
lipophilic material is dissolved in water immiscible organic solvent (e.g. cyclohexane) that is 
emulsified in an  aqueous phase [58]. Upon evaporation of the solvent, nanoparticle 
dispersion is formed by precipitation of the lipid in the aqueous medium. Siekmann and 
Westesen [59] produced cholesterol acetate nanoparticles with a mean size of 29 nm using 
solvent emulsification/evaporation technique. 
Other methods of lipid nanoparticle preparation include phase inversion and supercritical 
fluid (SCF) technology. 
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Figure 4. Production of lipid nanoparticles (SLN) by high pressure homogenisation (HPH) 
3.10. Characterization of lipid nanoparticle quality  
Quantitative analysis of particle characteristics such as morphological features can be very 
informative as biophysical properties are known to influence biological activity, 
biodistribution and toxicity. Several techniques are often used to assess nanoparticle 
characteristics such as lamellarity, size, shape and polydispersity [60]. Adequate and proper 
characterization of the lipid nanoparticles is necessary for quality control. However, 
characterization of lipid nanoparticles is a serious challenge due to the colloidal size of the 
particles and the complexity and dynamic nature of the delivery system.  
The important parameters which need to be evaluated for the lipid nanoparticles are particle 
size, size distribution kinetics (zeta potential), degree of crystallinity and lipid modification 
(polymorphism), coexistence of additional colloidal structures (micelles, liposome, super 
cooled melts, drug nanoparticles), time scale of distribution processes, drug content 
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(encapsulation efficiency and loading capacity), in vitro drug release and surface 
morphology.  
Particle size and size-distribution may be studied using photon correlation spectroscopy 
(PCS) otherwise known as dynamic light scattering (DLS), static light scattering (SLS), 
transmission electron microscopy (TEM), scanning electron microscopy (SEM), atomic force 
microscopy (AFM), scanning tunneling microscopy (STM), freeze fracture electron 
microscopy (FFEM) or cryoelectron microscopy (Cryo-EM). These microscopy techniques 
are also used  to study the morphology of nanoparticles. 
Among the imaging techniques, AFM has been widely applied to obtain the size, shape and 
surface morphological information on nanoparticles. It is capable of resolving surface details 
down to 0.01 nm and producing a contrasted and three-dimensional image of the sample. X-
ray diffraction and differential scanning calorimetric analysis give information on the 
crystalline state and polymorphic changes in the nanoparticles. Confocal laser scanning 
microscopy (CLSM) gives information on interaction of nanoparticles with cells. Nuclear 
magnetic resonance (NMR) can be used to determine both the size and the qualitative 
nature of nanoparticles. The selectivity afforded by chemical shift complements the 
sensitivity to molecular mobility to provide information on the physicochemical status of 
components within the nanoparticle. 
An important characterization technique for lipid nanoparticles is determination of solid 
state properties. This is very important in order to detect the possible modifications in the 
physicochemical properties of the drug incorporated into the lipid nanoparticles or the lipid 
matrix.  It has been proven that although particles were produced from crystalline raw 
materials,  the presence of emulsifiers, preparation method and high shear encountered (e.g. 
HPH) may result in changes in the crystallinity of the matrix constituents compared with 
bulk materials. This may lead to liquid, amorphous or only partially crystallized metastable 
systems [61]. Polymorphic transformations may cause chemical and physical changes (e.g. 
shape, solubility, melting point)  in the active and auxiliary substances. The solid state 
analysis of lipid nanoparticles is usually carried out using the following procedures: DSC, X-
ray diffraction, hot stage microscopy, Raman spectroscopy and Fourier-transform infrared 
spectroscopy. 
3.11. Drug incorporation and loading capacity 
Many different drugs have been incorporated in lipid nanoparticles. A very important point 
to judge the suitability of a drug carrier system is its loading capacity. The loading capacity 
is generally expressed in percent related to the lipid phase (matrix lipid  and drug). 
Westesen et al. [61] studied the incorporation of drugs using loading capacities of typically 1 
- 5%, but for ubidecarenone loading capacities of up to 50% were reported. Different loading 
capacities were obtained for other drugs [62]. Factors determining the loading capacity of a 
drug in the lipid include among others, solubility of drug in melted lipid; miscibility of drug 
melt and lipid melt; chemical and physical structure of solid lipid matrix; and polymorphic 
state of lipid material. 
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The prerequisite to obtain a sufficient loading capacity is a sufficiently high solubility of the 
drug in the lipid melt. This is why it is necessary to determine the solubility of a drug in the 
lipid matrix as a preformulation strategy. Typically, the solubility should be higher than 
required because it decreases when cooling the melt and might even be lower in the solid 
lipid. Solubility of a drug in the lipid melt could be enhanced by the addition of solubilizers. 
3.12. Drug release from lipid nanoparticles 
There have been many studies dealing with drug incorporation, however, there are 
distinctly less data available about drug release, especially information about the release 
mechanisms. Drug release from lipid nanoparticles could be conducted using different 
models and biorelevant media. Generally, artificial membranes, tissue constructs or excised 
skin are used as barriers. A major problem encountered with lipid nanoparticles is the burst 
release observed with these systems, however, a prolonged drug release could also be 
obtained with these systems. It is possible to modify the release profiles as a function of lipid 
matrix, surfactant concentration and production parameters (e.g. temperature) and by 
surface modification [40].  
The release profiles of drugs from lipid nanoparticles could be modulated to obtain 
prolonged release without burst effect, or to generate systems with tailored burst, followed 
by prolonged release. The burst can be exploited to deliver an initial dose when desired. It is 
important to note that the release profiles are not or only slightly affected by the particle 
size. Predominant factors for the shape of the release profiles are the production parameters 
(surfactant concentration, temperature) and the nature of the lipid matrix. During particle 
production of lipid nanoparticles by the hot homogenization technique, drug partitions 
from the liquid oil phase to the aqueous water phase. The amount of drug partitioning to 
the water phase will increase with the solubility of the drug in the water phase, that means 
with increasing temperature of the aqueous phase and increasing surfactant concentration 
as these two parameters directly affect the solubility of drugs in aqueous system.  
It was reported that there was a decrease in release with decrease in temperature for a drug 
encapsulated in lipid nanocapsule [63]. This decrease in drug release with decreasing 
temperature was attributed to an increased microviscosity of the oil delaying the drug 
diffusion out of lipid nanocapsule core into the aqueous release medium. The effect of 
ambient temperature on viscosity, however, was not limited to the internal oily core 
material but applies also to the external aqueous phase. 
Investigation of drug release from different wax matrix pellets using theophylline as a 
lipophilic drug showed that as the hydrophobicity of the wax increased, the drug release 
rate decreased. The more hydrophilic is the wax, the more it is susceptible to hydration by 
the release medium and therefore the faster the drug release. The drug release pattern was 
also highly dependent on the drug aqueous solubility. The release process was mainly 
affected by the relative affinity of the drug to the wax and the aqueous release medium [63]. 
Therefore, wax could be modified with compatible hydrophilic material to moderate drug 
release from lipid-based wax matrices. It was also found that minor temperature changes 
around 37 oC will not significantly influence the drug release from these lipid nanocapsules, 
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which excluded the option of a temperature-dependent release under in vivo conditions. zur 
Mühlen et al. [64] reported that interactions between drug and lipid molecules plays important 
role in controlling the drug release. These interactions could affect the viscosity of the solid 
lipid matrix leading to different release rates for different drugs although having similar 
lipophilic properties. They demonstrated that the development of sustained release SLN is 
possible by the proper choice of the drug and the lipid and their degree of interaction. 
3.13. Challenges of lipid nanoparticle drug delivery system 
One major problem with the intravenous administration of colloidal particles is their 
interaction with the reticulo-endothelial system (RES). Nanoparticles for medical 
applications are frequently given via parenteral administration. As with any foreign 
material, the body mounts a biological response to an administered nanoparticle. This 
response is the result of a complex interplay of factors, not just the intrinsic characteristics of 
the nanoparticle. In particular, most materials, upon contact with biological matrices, are 
immediately coated by proteins, leading to a protein “corona” [65]. Protein coronas are 
complex and variable. Certain components of the nanoparticle corona, called opsonins, may 
enhance uptake of the coated material by cells of the RES. The presence of opsonins on the 
particle surface creates a “molecular signature” which is recognized by immune cells and 
determines the route of particle internalization. The route of internalization affects the 
eventual fate of the nanoparticle in the body (i.e. its rate of clearance from the bloodstream, 
volume of distribution, organ disposition, and rate and route of clearance from the body). 
The cells of RES are capable of mopping up particles that they do not recognise as self i.e. 
particles they recognise as foreign. The negative effect can however, be remedied by linking 
of polyethylene glycol molecules to the lipid nanoparticles, thus increasing their 
hydrophilicity and the residence time of these particles in circulation. Alternatively, the lipid 
nanoparticles could be engineered to evade these RES cells by limiting the particle sizes to 
about 200 nm or less. It is believed that these cells do not recognise low nanometer-sized 
particles as foreign. Several other varied and unrelated challenges are encountered in lipid 
nanoparticle technology. These challenges constitute a serious research question which 
current strategies are targeted to address. 
3.13.1. Formation of perfect crystalline structure during storage  
Triglycerides crystallize in different polymorphic forms such as α, γ, β', and β- forms. 
Recrystallization from the melt results in the metastable α-polymorph which subsequently 
undergoes a polymorphic transition into the stable β-form via a metastable intermediate. 
The β-polymorph especially consists of a highly ordered, rigid structure with low loading 
capacity of drugs. Transition to the β-form via a metastable intermediate form leads to drug 
expulsion and inability to protect or prolong the release of the encapsulated drug. 
3.13.2. Physical stability  
The stability of lipid particulate systems is influenced by the size of the nanoparticles. Lipid 
nanoparticles are prevented from sedimentation by Brownian motion, but other instabilities 
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like Ostwald ripening and aggregation may occur. Since nanoparticles have a large specific 
surface area, stabilization of the surface with sufficient amounts of emulsifier(s) is necessary. 
The formulation of the colloidal carriers themselves is a difficult task due to many problems 
that arise from their colloidal state and specific pharmaceutical demands on such 
formulations. Stability in a pharmaceutical sense refers to a shelf life of usually 3-5 years. 
Shorter shelf lives will only be accepted in very special cases. However, for most systems of 
pharmaceutical interest the colloidal state is at its best metastable. The colloidal state may 
cause several additional instabilities, for example, due to the presence of large interfaces 
(adsorption-desorption processes, interactions in the stabilizer layer, higher risk of chemical 
instabilities, etc.). Since many colloidal administration systems are intended for intravenous 
use, stability is very crucial. Ability to be sterilized is also an added advantage.  
3.13.3. Gel formation 
The change in morphology of lipid nanoparticles from spheres to platelets is responsible for 
the gelation of solid lipid nanoparticle dispersions [66]. Depending on the composition, 
especially of the emulsifier(s) and the amount of lipid matrix, a gelation of the normally 
liquid dispersions can be observed on storage [66, 67]. By means of TEM and synchrotron 
measurements, the reason for the gelation was found. The gelation may derive from a 
reversible self-association of the particles due to a stacking of the platelets [68, 69]. This gel-
like feature of highly concentrated dispersions favours application as dermal drug delivery 
system since the viscoelastic features resemble those of semisolid creams [56]. In contrast, 
the lipid nanoparticle formulations for intravenous and ocular administration have to 
remain fluid. Phase transitions that would lead to an unusual lamellar gel phase (Lβ) should 
be investigated for in parenteral formulations. 
3.13.4. High water content of dispersions 
The high water content of lipid nanoparticles (70-95%) could lead to drug degradation and 
high cost of energy input during lyophilisation. During lyophilisation, the integrity of the 
nanoparticles could be affected if adequate croprotectant or lyoprotectant was not included 
in the formulation. Water free nanoparticles could be used in tablet production or the 
nanoparticle dispersion used as granulating fluid during production. SLN can be 
transformed into a powder by spray-drying. In any case, it is beneficial to have a higher 
solid content to avoid the need of having to remove too much water. For cost reasons, spray 
drying might be the preferred method for transforming SLN dispersions into powders, with 
the previous addition of a protectant [26]. 
3.13.5. Dosing problems  
Selection of appropriate dosage form for lipid nanoparticle may be a problem. Outside 
injectables, there is need to package lipid nanoparticles in appropriate dosage units e.g. 
dispersible powders or hard/soft gelatine capsules especially for oral administration. Since 
the stomach acidic environment and its high ionic strength favour particle aggregation, 
aqueous dispersions of lipid nanoparticles might not be suitable to be administered orally as 
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a dosage form. In addition, the presence of food will also have a high impact on their 
performance [70]. Packaging of SLN in a sachet for redispersion in water or juice prior to 
administration will allow an individual dosing by volume of the reconstituted SLN. This 
means additional step in packaging, which might result in introduction of additional 
technology and increase in the cost of the product. 
3.13.6. Coexistence of other colloidal structures in the system (e.g. liposome and vesicles in 
SLN and NLC containing phospholipids) 
Considerable amounts of emulsifiers are needed for the stabilization of lipid nanoparticles. 
If the emulsifiers redistribute from the particles into the aqueous phase, they can form 
colloidal structures like micelles or liposomes or other vesicular structures by self-assembly. 
Drugs can be solubilized within these structures, affecting drug release as well as drug 
loading capacity [70]. Hence the formation of additional colloidal structures has to be 
investigated for each formulation to enable further precautions to be taken to avoided it. The 
coexistence of liposomes and oil droplets was detected in an intravenous o/w nanoemulsion 
[71]. In solid lipid nanoparticle dispersion, additional liposomes were observed by means of 
cryo-TEM, although the amount was lower than in a corresponding emulsion [72]. In 
contrast to this, Schubert et al. [73] performed NMR, TEM and small angle X-ray scattering 
(SAXS) measurements and showed that no additional colloidal structures were formed. 
Drug nanocrystals could also be formed when the amount of the drug present far exceeds its 
solubility limit in the lipid matrix. 
3.13.7. Supercooling of nanoparticles 
Lipid nanoparticles prepared from triglycerides which are solid at room temperature may 
not necessarily crystallize on cooling to common storage temperatures. The particles can 
remain liquid for several months without crystallization (supercooled melt) [74]. 
Dispersions with lower melting points, in particular, monoacid triglycerides such as 
trilaurin or trimyristin, do not display melting transitions upon heating in differential 
scanning calorimeter or reflections due to crystalline nature in X-ray diffractometer after 
storage at room temperature. As confirmed by studies with quantitative 1H NMR 
spectroscopy, the matrix of the dispersed particles consists of liquid triglycerides in such 
particles. The particles have a high tendency toward supercooling. The critical crystallization 
temperature is mainly dependent on the composition of the triglyceride matrix and can also be 
modified by incorporated drugs. The degree of supercooling is much higher in the 
nanoparticles than for the bulk triglyceride. This supercooling could be taken advantage of 
and utilized as a delivery system of its own but this has to be planned for ab initio. 
3.14. Applications of lipid particulate drug delivery systems 
During the last decade, different substances have been entrapped into lipid nanoparticles 
ranging from lipophilic to hydrophilic molecules and including difficult compounds such as 
proteins and peptides.  
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3.14.1. Lipid nanoparticles as carriers for oral drug delivery 
Lipid nanoparticles such as SLN can be administered orally as dispersion, SLN-based tablet, 
pellets or capsules [70] or even as lyophilized unit dose powders for reconstitution for oral 
delivery. The stability of the particles in the GIT has to be thoroughly tested, since low pH 
and high ionic strength in the GIT may result in aggregation of the particles. In order to 
prove this, an investigation of the effect of artificial gastric fluids on different lipidic 
nanoparticle formulations was performed. The authors showed that a zeta potential of at 
least 8-9 mV in combination with a steric stabilization hinders aggregation under these 
conditions [75]. Additionally, for oral drug delivery, a release upon enzymatic degradation 
has to be taken into account [3, 76].  
The routes for particle uptake after oral application are transcellular (via the M cells in the 
Peyer’s patches or enterocytes) or paracellular (diffusion between the cells). However, the 
uptake via M cells is the major pathway, resulting in the transport of the particles to the 
lymph [77]. Uptake into the lymph and the blood was demonstrated by means of TEM and 
gamma counting of labelled SLN. It was found that uptake to the lymph was considerably 
higher than to the plasma [78], and as such, a reduced first pass effect concludes, as the 
transport via the portal vein to the liver is bypassed [79].  
SLN containing the antituberculosis drugs rifampicin, isoniazid and pyrazinamide have 
been studied in animals model and it was found that administration every 10 days could be 
successful for the management of tuberculosis [80].  
3.14.2. Lipid nanoparticles for parenteral drug delivery 
Lipid nanoparticles can be formulated for subcutaneous, intramuscular or intravenous 
administration. For intravenous administration, the small particle size is a prerequisite as 
passage through the needle and possibility of embolism should be considered. SLN offer the 
opportunity of a controlled drug release and the possibility to incorporate poorly soluble 
drugs. Additionally, especially for intravenous application, drug targeting via modification 
of the particle surface is possible, and for SLN formulation with a controlled release, higher 
plasma concentrations over a prolonged period of time can be obtained. Such systems form 
an intravenous depot. Further studies with different drugs such as idarubicin, doxorubicin, 
tobramycin, clozapine or temozolomide  also showed a sustained release  as described in a 
review paper by Harms and Müller-Goymann [81]. 
3.14.3. Lipid nanoparticles as carriers for peptides and proteins drugs 
Lipid nanoparticles have been extensively studied for the delivery of proteins and peptides 
[82]. Therapeutic application of peptides and proteins is restricted by their high molecular 
weight, hydrophilic character and limited chemical stability, which cause low 
bioavailability, poor transfer across biological membranes and low stability in the 
bloodstream. Most of the available peptides and proteins are delivered by injection, but their 
short half life demands repeated doses that are costly, painful and not well tolerated by 
patients. Lipid nanoparticles could be useful for peptide and protein delivery due to the 
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stabilizing effect of lipids and to the absorption promoting effect of the lipidic material that 
constitute this kind of nanoparticles [83]. The use of niosomes and liposomes as adjuvants 
for the delivery of Newcastle disease virus to chicks has been reported [14].   
3.14.4. Lipid nanocarriers for nasal vaccination 
The use of lipid nanocarriers provides a suitable way for the nasal delivery of antigenic 
molecules. Besides improved protection and facilitated transport of the antigen, 
nanoparticulate delivery systems could also provide more effective antigen recognition by 
immune cells. These represent key factors in the optimal processing and presentation of the 
antigen, and therefore in the subsequent development of a suitable immune response. In this 
sense, the design of optimized vaccine nanocarriers offers a promising way for nasal 
mucosal vaccination [82]. 
3.14.5. Lipid nanoparticles as carriers in cosmetic and dermal preparation  
Lipid nanoparticles can be incorporated into a cream, hydrogel or ointment to obtain 
semisolid systems for dermal applications. Another possibility is to increase the amount of 
lipid matrix in the formulation above a critical concentration, resulting in semisolid 
formulations [84]. The substances used for the preparation of dermal SLN are rather 
innocuous since they are mostly rated as GRAS and many of them are used in conventional 
dermal formulations. This resulted in the first dermal formulations containing SLN for 
cosmetic purposes entering the market  [85].  
Due to the adhesiveness of small particles, SLN adhere to the stratum corneum forming a 
film as this films have been shown to possess occlusive properties [86]. It was shown that 
the degree of crystallinity has a great impact on the extent of occlusion by the formulation. 
With increasing crystallinity the occlusion factor increases as well [87]. This explains why 
liquid nanoemulsions in contrast to SLN do not show an occlusive effect and why the extent 
of occlusion by NLC compared to SLN is reduced. Other parameters influencing the 
occlusion factor are the particle size and the number of particles. Whilst with increasing size 
the factor decreases, an increase in number results in an increase in the extent occlusion [88]. 
The occlusive effect leads to reduced water loss and increased skin hydration. Highly 
crystalline SLN can be used for physical sun protection due to scattering and reflection of 
the UV radiation by the particles. A high crystallinity was found to enhance the 
effectiveness and was also synergistic with UV absorbing substances used in conventional 
sunscreens [89]. Similarly synergism was observed on the sun protection factor and UV-A 
protection factor exhibited by the incorporation of the inorganic sunscreen, titanium-dioxide 
in NLC of carnauba wax and decyl oleate [90]. 
3.14.6. Lipid nanoparticles for ocular application 
The eye possesses unique challenges with respect to drug delivery especially with respect to 
the posterior segment and treating vision threatening diseases. Poor bioavailability of drugs 
from ocular dosage form is mainly due to the pre-corneal loss factors which include tear 
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dynamics, non-productive absorption, transient residence time in the cul-de-sac, and relative 
impermeability of the corneal epithelial membrane. Due to the adhesive nature of the small 
nanoparticles, these negative effects can be reduced. For ocularly administered SLN an 
increase in bioavailability was observed in rabbits by Cavalli et al. [91] using tobramycin ion 
pair as the model drug. Various in vitro studies show a prolonged and enhanced permeation 
when the drug is incorporated in lipid nanoparticles [39]. For systems containing 
phospholipids, a further improved permeation of diclofenac sodium was observed [31]. 
3.14.7. Pulmonary application of lipid nanoparticles 
Pulmonary drug application offers the advantage of minimizing toxic side effects if a local 
impact is intended. Systemic delivery can be achieved through pulmonary delivery, offering 
the advantage of bypassing the first pass effect, as well as offering a large absorptive area, 
extensive vasculature, easily permeable membrane and low extracellular and intracellular 
enzyme activities [92]. A problem of this method of administration is the low bioavailability. 
SLN can easily be nebulized to form an aerosol of liquid droplets containing nanoparticles 
for inhalation [82]. In vivo studies showed that the administered drugs (rifampicin, isoniazid 
and pyrazinamide for the treatment of tuberculosis) resulted in a prolonged mean residence 
time and a higher bioavailability than the free drug [93, 94]. 
3.14.8. Application of liquid crystal drug delivery systems 
The spontaneous self assembly of some lipids to form liquid crystalline structures offers a 
potential new class of sustained release matrix. The nanostructured liquid crystalline 
materials are highly stable to dilution. This means that they can persist as a reservoir for 
slow drug release in excess fluids such as the GIT or subcutaneous space, or be dispersed 
into nanoparticle form, while retaining the parent liquid crystalline structure. The rate of 
drug release is directly related to the nanostructure of the matrix. The particular geometry 
into which the lipids assemble can be manipulated through either the use of additives to 
modify the assembly process, or through modifying conditions such as temperature, thereby 
providing a means to control drug release.  
Liquid crystal depot could be injected as a low-viscosity solution. Once in the body, it self-
assembles and encapsulates the drug in a nanostructured, viscous liquid crystal gel. The 
drug substance is then released from the liquid crystal matrix over a time period, which can 
be tuned from days to months. The liquid crystal depot system is capable of providing in 
vivo sustained release of a wide range of therapeutic agents over controlled periods of time. 
Liquid crystal nanoparticles can be combined with controlled-release and targeting 
functionalities. The particles are designed to form in situ at a controlled rate, which enables 
an effective in vivo distribution of the drug. The system has been shown to give more stable 
plasma levels of peptides in comparison to competing microsphere and conventional oil-
depot technologies [21, 95].  
Oral liquid crystal DDS are designed to address the varied challenges in oral delivery of 
numerous promising compounds including poor aqueous solubility, poor absorption, and 
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large molecular size. Compared with conventional lipid or non-lipid carriers, these show 
high drug carrier capacity for a range of sparingly water-soluble drugs. For drugs 
susceptible to in vivo degradation, such as peptides and proteins, liquid crystal nanoparticles 
protect the sensitive drug from enzymatic degradation. The system also addresses 
permeability limitations by exploiting the lipid-mediated absorption mechanism. For water-
soluble peptides, typical bioavailability enhancements range from twenty to more than one 
hundred times. In an alternative application large proteins have been encapsulated for local 
activity in the GIT. Liquid crystal nanoparticle systems can be designed to be released at 
different absorption sites (e.g., in the upper or lower intestine) which is important for drugs 
that have narrow regional absorption windows. 
With regards to topical application, liquid crystal systems form a thin surface film at 
mucosal surfaces consisting of a liquid crystal matrix, whose nanostructure can be 
controlled for achieving an optimal delivery profile. The system also provides good 
temporary protection for sore and sensitive skin. Their unique solubilizing, encapsulating, 
transporting, and protecting capacity is advantageously exploited in liquid and gel products 
used to increase transdermal and nasal bioavailability of small molecules and peptides.  
3.15. Lipid nanoparticles in drug targeting 
Nanoscale lipid materials containing drugs and diagnostics are being developed to image 
the distribution of tumour cells in the body, target and attach to cancerous cells, destroy 
unwanted cells via ablation or interference with cellular functions. Drug targeting might 
overcome the problem of repeated administration by facilitating the efficacy of drug 
administered systemically and attenuating side effects on healthy tissues. Ultimately, lipid 
nanoparticles represent versatile DDS, with the ability to overcome physiological barriers 
and guide the drug to specific cells or intracellular compartments by means of passive or 
ligand-mediated targeting mechanisms. 
There are many research reports dealing with targeting of drugs to certain cellular targets in 
the organs using lipid nanoparticles. The knowledge of the pathophysiological/passive 
targeting approaches used in cancer chemotherapy is used to develop nanocarriers for 
targeting drug to appropriate cancer cells in the body. Small molecules administered 
systemically are easily eliminated through the kidney into the urine and distributed equally 
not only in the target tissue but also in other healthy tissues, resulting in less efficacy and 
more possible side effects [96]. On the other hand, large molecules have longer half-life in 
the blood and tend to be passively delivered to the lesions with highly permeable vessels in 
neovascularization and inflammation. This tendency is remarkable especially in solid 
tumors because of high density of neovascular vessels and immature lymph systems, and is 
termed enhanced permeability and retention (EPR) effect. Because of the successes being 
recorded from in vitro experiments, lipid nanoparticles have been subject of further 
investigation for drug targeting to the brain, several types of cancer, posterior segments of 
the eye, otic (inner ear) diseases, and delivery of nucleic acids and genes, utilizing the both 
active and passive targeting opportunities [97]. 
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3.16. Scale up issues and ultimate dosage form development  
Large scale production of lipid nanoparticles is possible using lines available in 
pharmaceutical plants. In spite of intensive research on colloidal drug carrier systems, in 
some cases for several decades (e.g., with lipid emulsions or liposomes), remarkably few 
have been introduced into the market [98, 99] as presented in Table 3 indicating that there 
seem to be problems either with the underlying concepts or with the formulation of 
adequate colloidal carriers, or both. Most of the products are cosmetic products. In this 
context, it has, of course, to be taken into account that the development and registration of a 
new type of administration system may take as long for a new drug or novel formulation 
thereof; that means up to 10 years or even more. Therefore, products will appear on the 
market only after considerable period of time when  the concept has been successfully 
realized. 
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extract from coconut, wild 
indigo, noni extract  
 
NanoLipid Restore CLR  
 
Nanolipid Q10 CLR  
 
Nanolipid Basic CLR  














Black currant seed oil containing 
ω-3 and ω-6 unsaturated fatty 
acids  
coenzyme Q10 and black 
currant seed oil  
caprylic/capric triglycerides  
black currant seed oil and 
manuka oil  
IOPE SuperVital  
- Cream  
- Serum  











coenzyme Q10, ω-3 und ω-6 
unsaturated fatty acids  
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Product name  Producer Market 
entry date  
Main active ingredients  
- Extra moist softener  
- Extra moist emulsion  
  
NLC Deep Effect Eye Serum  
NLC Deep Effect Repair 
Cream  
NLC Deep Effect 
Reconstruction Cream  
NLC Deep Effect 










coenzyme Q10, highly active 
oligo saccharides  
Q10, TiO2, highly active oligo 
saccharides  
Q10, Acetyl Hexapeptide-3, 
micronized plant collagen, high 
active oligosaccharides in 









Macadamia Ternifolia seed oil, 
Avocado oil, Urea, Black currant 
seed oil  
Swiss Cellular White  
Illuminating Eye Essence  
Swiss Cellular White  
Intensive Ampoules  
 





Glycoprotiens, Panax ginseng 
root extract, Equisetum Arvense 
extract, Camellia Sinensis leaf 
extract, Viola Tricolor Extract  
SURMER Creme  









Kukuinut oil, Monoi Tiare 
Tahiti®, pseudopeptide, 
hydrolized wheet protien  











Olea Europaea Oil, Panthenol, 
Acacia Senegal, Tocopheryl 
Acetate  
Olea Europaea Oil, Prunus 
Amygdalus Dulcis Oil, 
Hydrolized Milk Protein, 
Tocopheryl Acetate, Rhodiola 
Rosea Root Extract, Caffeine  
Table 3. Examples of cosmetic products currently on the market containing lipid nanoparticles 
(Adapted from [98, 99]). 
4. Future prospects of novel lipid particulate drug delivery systems 
Novel lipid based nanoparticles offer a highly versatile platform that should be considered 
when working with drugs that present solubility and/or bioavailability challenges. An 
increasing number of drugs under development are poorly water soluble and therefore have 
poor bioavailability. These are designated BCS class II and class IV drugs. Creative 
formulation techniques are required to produce finished drug products of these drugs that 
have acceptable pharmacokinetics. A common formulation approach with such compounds 
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is to focus on creating and stabilizing very small particles of the drug in an attempt to 
increase the surface area available for dissolution in vivo, and hence the rate of dissolution, 
and consequently plasma or tissue levels of drug. Shelf-life stability and enzymatic 
degradation are two main areas of concern, and formulation design focuses on stabilizing 
the drug in storage and protecting it from endogenous enzyme degradation until it reaches 
its therapeutic target. These novel DDS are well suited for the formulation of these 
bioactives. 
Lipid nanoparticle DDS can be employed for the delivery of phytomedicines intended for 
oral and topical administration, which are the main routes of administration of 
phytomedicinals. This application holds great promise in the development and use of 
phytomedicines considering the difficulties of their delivery owing to their physicochemical 
properties. Since many phytomedicines usually possess different pharmacological activities, 
the delivery can be targeted to specific part(s) of the body where action is desired by means 
of lipid nanoparticle technology [60]. Thus, undesired effects and wastage of materials 
would be avoided. The implication is that with efficiency of preparation, only required 
quantity is utilized for formulation and adequate dose is absorbed and successfully 
delivered to the target for the desired activity. Lipid nanoparticle formulation of 
phytomedicinals would find useful applications in nanomedicine especially where targeted 
delivery is important such as in the treatment of cancer. 
5. Conclusions 
The use of lipid particles as drug carrier systems has been favoured recently as result of the 
GRAS status of the excipients and their traditional use in other food and pharmaceutical 
products. Lipids and lipid nanoparticles are promising delivery systems for oral 
administration of small molecule drugs, proteins and peptides. Lipid formulations of drugs  
are able to control the release of drugs and reduce absorption variability. The oral 
administration of lipid nanoparticles is possible as aqueous dispersion or alternatively 
transformed into a traditional dosage forms such as tablets, pellets, capsules, or powders in 
sachets. The ability to incorporate drugs into lipid nanocarriers offers a new prototype in 
drug delivery that could be used for passive and active drug targeting. Lipid nanoparticles 
for topical application could be formulated with high content of lipid matrix or dispersed in 
creams or gels to give it ‘body’. With the development and interest in lipid particulate drug 
delivery systems shown by pharmaceutical formulation scientists, a future full of lipid 
nanoparticle products in the market is envisaged. 
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